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 Primary liver cancer incidence and mortality rates
have rapidly increased between 1997 and 2014.
 The rate of increase in hepatocellular carcinoma
incidence rates has plateaued since around 2014.
 Hepatocellular carcinoma incidence and mortality
rates were highest in Scottish men.
 Survival has improved, particularly for hepatocel-
lular carcinoma, but remains poor.https://doi.org/10.1016/j.jhepr.2021.100232Many more people are getting liver cancer, particu-
larly the subtype hepatocellular carcinoma, than 20
years ago. Men in Scotland are most likely to get liver
cancer and to die from it. Survival after liver cancer
diagnosis is getting longer but still less than half are
alive after 1 year.
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Background & Aims: The incidence of primary liver cancer (PLC) is increasing in Western Europe. To understand trends over
time and the current burden in the UK, a detailed analysis of the epidemiology of PLC and its subtypes was conducted.
Methods: Data on PLCs diagnosed during 1997–2017 were obtained from population-based, nationwide registries in the UK.
European age-standardised incidence (ASR) and incidence-based mortality rates (ASMR) per 100,000 person-years were
calculated overall and by sex and UK-nation. Annual percentage change in rates was estimated using Joinpoint regression.
One-, 2-, and 5-year age-standardised net survival was estimated.
Results: A total of 82,024 PLCs were diagnosed. Both hepatocellular carcinoma (HCC) incidence and mortality rates trebled
(ASR 1.8–5.5 per 100,000, ASMR 1.3–4.0). The rate of increase appeared to plateau around 2014/2015. Scottish men consis-
tently had the highest HCC incidence rates. PLC survival increased, driven by a substantial increase in the proportion that are
HCC (as prognosis is better than other PLCs) and in HCC survival (change in 1-year survival 24–47%). Intrahepatic chol-
angiocarcinoma was the most common PLC in women and 1-year survival improved from 22.6% to 30.5%.
Conclusions: PLC incidence has been increasing rapidly but, as most risk factors are modifiable, it is largely a preventable
cancer. This rate of increase has slowed in recent years, possibly attributable to effective treatment for hepatitis C. As other
risk factors such as obesity and diabetes remain prevalent in the UK, it is unlikely the considerable burden of this disease will
abate. While improvements in survival have been made, over half of patients are not alive after 1 year, therefore further
progress in prevention, early detection, and treatment innovation are needed.
Lay summary: Many more people are getting liver cancer, particularly the subtype hepatocellular carcinoma, than 20 years
ago. Men in Scotland are most likely to get liver cancer and to die from it. Survival after liver cancer diagnosis is getting longer
but still less than half are alive after 1 year.
Crown Copyright © 2021 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is
an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Introduction
Primary liver cancer (PLC) is the fourth leading cause of cancer-
related mortality worldwide, causing an estimated 800,000
deaths in 2018.1 Incidence rates have been rising in many
countries globally but particularly rapidly in Western Europe,Keywords: Primary liver cancer; Hepatocellular carcinoma; Intrahepatic chol-
angiocarcinoma; Incidence; Mortality; Survival.
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amongst the cancers with the most rapid rate of growth in both
incidence and mortality in recent decades, and is projected to be
the cancer with the highest average annual increase over the
next 15 years.3 Survival is particularly poor for this cancer with
5-year relative survival estimates below 10%.4
The main PLC subtype, hepatocellular carcinoma (HCC), is an
epithelial tumour which shows hepatocytic differentiation and
primarily occurs against a backdrop of cirrhosis, caused by factors
such as chronic viral hepatitis, alcohol consumption, and non-
alcoholic fatty liver disease. The second most common subtype,
intrahepatic cholangiocarcinoma (ICCA), is an epithelial tumour
showing biliary differentiation in the liver, and often occurs in
patients with no known risk factors. A small proportion of PLCs
have mixed features of both HCC and ICCA. There are also rare
Research articlesubtypes such as hepatoblastoma, Kupffer cell sarcoma, and other
carcinomas and sarcomas. The distribution of risk factors, and
subsequently liver cancer rates, change with time owing to factors
such as changing behaviours, large-scale public health initiatives
such as vaccination and other forms of infection prevention, and
innovation in treatment of underlying liver diseases. Under-
standing the current burden of liver cancer and trends over time
can quantify the public health concern, identify the need for
public health interventions aimed at prevention and indicate
whether it is necessary to scale-up facilities and training to meet
increasing demand. Further examination by subtype is important
as the causes, treatment, and outcomes are quite different.
The HCC-UK BASL/National Cancer Registration and Analysis
Service (NCRAS) partnership was formed to facilitate a wide pro-
gramme of research relating to HCC, primarily using the detailed
data available within the NCRAS on all cancer patients resident in
England. Here, within the framework of this partnership and
including corresponding data from the Welsh Cancer Intelligence
and Surveillance Unit, the Northern Ireland Cancer Registry, and
the Scottish Cancer Registry, the incidence, incidence-based mor-
tality and survival trends in PLC and its subtypes in the UK and
each constituent nation between 1997 and 2017 were examined.Patients and methods
Data sources
Patient-level data on PLC tumours, defined using the 10th edition
of the International Classification of Diseases (ICD-10) code C22,
diagnosed between 1997 and 2017 were obtained from the
population-based, nationwide registries in Wales, Scotland,
Northern Ireland (NI), and England. Patient-level data collected
included ICD-10 code, second edition of the ICD for Oncology
(ICD-O-2) morphology code, diagnosis year, death year, days
from diagnosis to death, or latest vital status date (31 December
2017 for Wales, 31 December 2018 for NI and Scotland, and 06
February 2019 for England), vital status (alive/dead/emigrated),
age at diagnosis (5-year age bands), sex, underlying cause of
death (ICD-9 or ICD-10 code) and basis of diagnosis. Only those
tumours with a malignant ICD-O-2 behaviour code were
included.
For incidence, all new diagnoses in the period 1997–2017
were included. For mortality and survival calculations, the first
liver tumour only was included. Records with a date of death
before date of diagnosis (N = 27) and those with the ICD-O-2
morphology code 8162, Klatskin tumour (perihilar CCA), were
excluded (N = 298). For mortality, those with missing cause of
death were excluded (N = 913, 0.9% of deaths). For survival an-
alyses those that embarked (as no last vital status date, N = 170),
registrations based on death certificate only (and autopsy di-
agnoses only in the Scottish data) (N = 3,067) and those aged <15
years (N = 493) were excluded. ICD-10 codes and ICD-O-2
morphology codes were used to define subtypes of PLC as out-
lined in the Supplementary information and Table S1.
Mid-year population data for 1997–2017 were obtained from
the Office for National Statistics.5 Life tables in 5-year age bands,
by sex and calendar year of death for the UK overall and for
England and Wales, Scotland, and NI separately were obtained
from the Human Mortality Database6 for 1997–2016. For esti-
mation of survival in 2017, 2016 life tables were used.JHEP Reports 2021Statistical analysis
Incidence
European age-standardised7 incidence (ASR) and incidence-
based mortality (ASMR) rates per 100,000 person-years and
Dobson confidence intervals were calculated using the distrate
command in Stata.8 Estimates from 3-year rolling cohorts were
used for graph smoothing.
Mortality
Standard mortality, which uses death certificate coding to count
the number of deaths from a particular cause in a population
per year, results in mortality rates that are higher than inci-
dence rates for ICCA (Fig. S1). This may, in part, be as a result of
over-recording of ICCA on death certificates, which use the ICD-
10 system, as CCA is coded as intrahepatic (C22.1) if no tumour
location is given. To resolve this and to more accurately identify
PLC deaths by subtype, an incidence-based mortality approach
was taken where the detailed cancer registry diagnostic data
was used to identify all those with primary liver tumours and
classify the subtype, and the death certificate cause of death
used to identify the cancer-related deaths in these patients.
Both deaths from liver cancer (C22) and extrahepatic chol-
angiocarcinoma (C24.0) were included to ensure any deaths
coded as intrahepatic CCA in the registry and extrahepatic CCA
on the death certificate were captured. Within each registry
cancer registration officers review data from multiple sources
to identify new cancer cases and classify tumours according to
the ICD-O-2 system which is a cancer-specific coding system
that assigns a specific site, morphology, and behaviour code to
each tumour.9 As only diagnoses from 1997 were available,
mortality rates are presented for 1999 onwards. A 2-year ‘run-
off’ period was identified as being sufficient in sensitivity ana-
lyses on English data including diagnoses pre-1997 and those
from 1997 only (Fig. S1).
Joinpoint regression modelling was used to model trends in
incidence and incidence-based mortality rates and identify
timepoints when significant changes occurred, constrained to a
maximum of 3 joinpoints (Joinpoint Regression Program, Version
4.7.0, Statistical Methodology and Applications Branch, Surveil-
lance Research Program, National Cancer Institute). Annual per-
centage change (APC) was calculated for each segment, and
average APC (AAPC) for the whole period.
Survival
One-, 2-, and 5-year age-standardised net survival was calculated
for 2- and 5-year cohorts using the strs command in Stata and
the cohort approach.10 Survival was only estimated for years
with complete follow-up. The Brenner method of age-
standardisation was applied.11 One day was added to survival
times of 0 (i.e. diagnosis and death on the same day). Survival
estimates were supressed if there were no deaths or data in at
least 1 age band, less than 10 in a group, the standard error
was greater than 0.2, 2-year survival was greater than 1-year
survival, and/or the follow-up time was insufficient in a cohort.
Estimates from 5-year rolling cohorts were used for graph
smoothing.
All analyses were conducted using Stata version 15.1 Stata-
Corp, 2017, Stata Statistical Software: Release 15 (StataCorp,
College Station, TX, USA).2vol. 3 j 100232
Results
Overview
Overall, in the UK 82,024 PLCs were diagnosed between 1997
and 2017 and 58,348 individuals died from their liver cancer
between 1999 and 2017 (Table 1). The age-standardised inci-
dence rate for the whole period was 7.3 per 100,000. Ninety
percent of PLCs occurred in those aged 50 years or older and
ICCA patients were slightly older on average than HCC patients
(Fig. S2). The age distribution was wide in patients with other
liver tumours, reflecting the diverse tumours in this group. Over
60% of PLCs were in men (77% of HCCs, 47% of ICCAs, and 58% of
other liver tumours) and PLC incidence rates were over twice as
high in men than in women (10.5 vs. 4.7 per 100,000, respec-
tively). A total of 50.5% of PLCs were HCCs (ASR 3.7 per 100,000),
37.1% were ICCAs (ASR 2.7 per 100,000), and 12.4% other or un-
specified liver cancers (ASR 0.9 per 100,000). These proportions
varied by nation; in Scotland and NI approximately 60% of PLCs
were HCC and 30% ICCA, whereas in England and Wales
approximately 50% were HCC and 40% ICCA (p for from chi-
squared test for difference between nations <0.001). Scotland
had the highest PLC incidence rate (ASR 8.9 per 100,000) and NI
the lowest (ASR 6.3 per 100,000). The overall incidence-based
age-standardised mortality rate was 5.2 per 100,000. A total of
47.9% were deaths from HCCs, 42.5% from ICCA, and 9.5% from
other and unspecified liver cancers. In general, mortality rates
followed similar patterns to incidence (higher in men than in
women and highest in Scotland and lowest in NI). However, the
overall mortality rate for ICCA (2.2 per 100,000) was nearly as
high as for HCC (2.5 per 100,000).Trends by subtype, nation, and sex
PLC
In the UK, PLC incidence increased from 4.4 per 100,000 in 1997
to 9.6 in 2017, an AAPC of 4.1% (95% CI 3.4–4.7; Fig. S3 and
Table 1). The Joinpoint trend analysis indicated the fastest in-
crease in PLC incidence in the UK was between the years 2003
and 2014 (APC 5.9% per year, 95% CI 5.3–6.4) and after this it
plateaued (-1.3% per year, 95% CI -4.1 to 1.5). The pattern of a
rapid increase in incidence rates then a plateau was seen in both
men and women and across nations (Fig. 1A), although in NI data
were sparse and therefore trends less clear. The highest PLC
incidence rates were seen in Scottish men, reaching a peak of
20.1 per 100,000 in 2013 (Table S2). The mortality rate changed
from 3.3 per 100,000 in 1999 to 7.5 in 2017, increasing 5.1% per
year (95% CI 4.8–5.3) until 2013 and then 2.4% per year (95% CI
1.1–3.8), not reaching plateau. As with incidence, the highest
mortality rates were seen in Scottish men (ASMR in 2017: 13.9
per 100,000).
HCC
HCC incidence increased from 1.8 to 5.5 per 100,000, an AAPC
increase of 5.9% per year. The fastest rate of growth was from
1997 to 2015 (APC 6.8% per year, 95% CI 6.4–7.2 UK, all persons),
after which it plateaued (APC 2015–2017 -1.5%, 95% CI -8.7 to 6.3;
Table 1). When further analysed by sex, the plateau was seen
mainly in men (Table 2 and Fig. 1B), in whom rates overall were
over 4 times higher than in women. For women, the best-fitting
model had no joinpoints and incidence rates rose 5.7% per year
from 1997 to 2017 (data not shown). The highest HCC rates were
in Scottish men (peak ASR in 2013 at 15.0 per 100,000 (Table S3).
The ASMR for HCC increased from 1.3 to 4.0 per 100,000 and theJHEP Reports 2021increase was constant (there were no joinpoints) at 5.8% per year
(95% CI 5.4–6.1). In 2017 the highest mortality rates were in
Scottish men (10.3 per 100,000), 2.6 times higher than the HCC
mortality rates in all persons in the UK (4.0 per 100,000).
ICCA
ICCA incidence also increased, from 1.8 to 3.3 per 100,000, an
AAPC of 3.4%. The most rapid rise was 1997–2009 (APC 4.4%, 95%
CI 3.6–5.3) and then this slowed to 2.0% per year (95% CI 0.8–3.2)
between 2009 and 2017 (Table 1). When analysed by nation this
pattern was seen in England, but in other nations the ICCA rates
were more variable and trends less clear (Fig. 1C). Incidence rates
were very similar in men and women with ICCA. ASMRs were
close to incidence rates (change from 1.4 to 3.0 per 100,000,
AAPC 3.8% per year) and did not significantly diverge from
incidence over time. Overall, ICCA incidence and mortality rates
were similar in England, Scotland and Wales, but slightly lower
in NI, although because of sparse data the confidence limits are
wide.
Other and unspecified liver tumours
There was variation but no clear trend in incidence rates (ASR
change 0.76–0.87, AAPC 0.3%, 95% CI -1.9 to 2.6) or mortality
rates for other liver tumours (AAPC 0.1%, 95% CI -4.3 to 4.7;
Fig. 1D).
Detailed year-by-year estimates of incidence and mortality
rates by nation, sex, and subtype are given in Tables S2–S5.
Survival
For PLC cases 1-, 2-, and 5-year net survival approximately
doubled over the study period, reaching 40.6% (2013–2017),
27.2% (2012–2016) and 14.3% (2009–2013), respectively (Table 3
and Fig. 2 and S6). Survival varied by subtype; while 1-year HCC
survival nearly doubled from 23.7% in 1997–2001 to 46.7% in
2013–2017, ICCA survival increased by about a third from 22.6%
to 30.5% in the same period. One-year survival for other PLCs
trebled, from 13.2% to 37.9%. Two- and 5-year survival change
followed a similar pattern. Throughout the study period, net PLC
survival appeared highest in Scotland, as it had higher HCC 1-, 2-,
and 5-year survival than other nations (net 1-year HCC survival
in Scotland was 52.4% in 2013–2017 compared with 46.2% in
England, 42.0% inWales, and 45.4% in NI). Although ICCA survival
in the most recent cohorts were comparable between countries,
NI and then England saw the largest improvements over the
study period. Sex did not appear to be strongly associated with
survival within subtype (Fig. S4). Complete survival estimates by
sex, nation, subtype, and cohort are given in Tables S6–S8.Discussion
Main findings
These results from this HCC-UK BASL/NCRAS partnership study
of PLC epidemiology in the UK over 20 years show that incidence
and incidence-based mortality rates from this largely prevent-
able disease more than doubled, primarily driven by a trebling in
HCC rates. The rapid rate of increase in HCC appears to have
plateaued since around 2014/15. Men in Scotland had the highest
HCC burden, which reached a peak ASR of 15.0 per 100,000 in
2013. ICCA incidence also increased and was the most common
PLC in women. PLC survival is improving; it has more than
doubled in last 20 years mainly because of the increase in HCC
survival, but also an increase in the proportion of PLCs that are3vol. 3 j 100232










per 100,000 95% CI Time period APC 95% CI
Overall
82,024 6.3 7.3 (7.2–7.3) AAPC 1997–2017 4.1* (3.4–4.7) 58,348 4.5 5.2 (5.2-5.2) AAPC 1999-2017 4.5* (4.1–4.8)
1997–2003 3.6* (2.0–5.1) 1999-2013 5.1* (4.8–5.3)
2003–2014 5.9* (5.3–6.4) 2013-2017 2.4* (1.1–3.8)
2014–2017 -1.3 (-4.1–1.5)
Sex
Men 52,258 8.2 10.5 (10.4–10.6) AAPC 1997–2017 4.5* (3.8–5.2) 36,373 5.7 7.4 (7.3-7.5) AAPC 1999-2017 4.4* (3.9–4.8)
1997–2014 5.4* (5.0–5.8) 1999-2013 4.9* (4.6–5.3)
2014–2017 -0.6 (-4.6–3.5) 2013-2017 2.5* (0.8–4.3)
Women 29,766 4.5 4.7 (4.6–4.7) AAPC 1997–2017 3.6* (2.9–4.2) 21,975 3.3 3.5 (3.4-3.5) AAPC 1999-2017 4.2* (3.7–4.8)
1997–2003 2.6* (0.9–4.2) 1999-2013 4.8* (4.4–5.3)
2003–2013 5.7* (5.0–6.4) 2013-2017 2.2 (0.0–4.4)
2013–2017 -0.1 (-2.1–1.9)
Country
England 67,177 6.2 7.1 (7.1–7.2) AAPC 1997–2017 4.5* (3.8–5.2) 47,840 4.4 5.1 (5.1-5.1) AAPC 1999-2017 4.5* (4.1–4.9)
1997–2014 5.4* (5.0–5.8) 1999-2012 5.3* (4.9–5.7)
2014–2017 -0.4 (-4.4–3.6) 2012-2017 2.6* (1.4–3.7)
Wales 4,502 7.1 7.5 (7.3–7.8) AAPC 1997–2017 3.2* (1.0–5.5) 3,232 5.1 5.4 (5.2-5.6) AAPC 1999-2017 4.0* (3.0–4.9)
1997–2015 4.7* (3.8–5.7)
2015–2017 -9.2 (-27.5–13.7)




NI 1,773 4.8 6.3 (6.0–6.6) AAPC 1997–2017 4.5* (3.3–5.8) 1,189 3.2 4.3 (4-4.5) AAPC 1999-2017 5.6* (3.9–7.4)
Subtype
HCC 41,454 3.2 3.7 (3.6–3.7) AAPC 1997–2017 5.9* (5.1–6.7) 27,970 2.2 2.5 (2.5-2.5) AAPC 1999-2017 5.8* (5.4–6.1)
1997–2015 6.8* (6.4–7.2)
2015–2017 -1.5 (-8.7–6.3)
ICCA 30,402 2.4 2.7 (2.7–2.8) AAPC 1997–2017 3.4* (2.8–4.1) 24,813 1.9 2.2 (2.2-2.3) AAPC 1999-2017 3.8* (3.3–4.3)
1997–2009 4.4* (3.6–5.3) 1999-2009 5.0* (4.3–5.8)
2009–2017 2.0* (0.8–3.2) 2009-2017 2.2* (1.4–3.0)
Other 10,165 0.8 0.9 (0.9–0.9) AAPC 1997–2017 0.3 (-1.9–2.6) 5,563 0.4 0.5 (0.5-0.5) AAPC 1999-2017 0.1 (-4.3–4.7)
1997–2005 -2.5 (-5.8–0.9) 1999-2001 -16.3 (-36.2–9.7)
2005–2013 9.7* (5.9–13.7) 2001-2011 3.3* (0.8–5.9)
2013–2017 -11.0* (-17.3–4.2) 2011-2014 13.8 (-8.8–41.9)
2014-2017 -10.9* (-20.2–0.5)
AAPC from best-fitting model given. If model has >1 joinpoint, APC for each time-period is also given. *The APC or AAPC is significantly different from zero at the alpha = 0.05 level. AAPC, average annual percentage change; APC,
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Fig. 1. Age-standardised incidence and incidence-based mortality. (A) Primary liver cancer; (B) hepatocellular carcinoma; (C) intrahepatic chol-
angiocarcinoma; (D) other and unspecified liver tumours. Estimates from 3-year rolling cohorts. ASR, age-standardised incidence rate per 100,000.HCCs (as prognosis is better in HCC than other PLCs). ICCA sur-
vival did not improve as substantially, and the incidence rates
remained close to mortality rates. Despite improving PLC sur-
vival, mortality increased because of increasing incidence.
Strengths and limitations
This comprehensive analysis of the epidemiology of liver cancer
in the UK over 20 years was conducted on population-level data
from high quality cancer registries with near complete popula-
tion coverage. It is the first study to examine PLC incidence,
incidence-based mortality and survival by subtype, sex, and UK
nation. Calculation of net-survival allows estimation of disease-
specific survival and age-standardisation allows comparison of
survival where the background mortality may differ, e.g. across
time points or regions. The incidence-based mortality method
used gives a good estimation of the true mortality rates in a
registry with long follow up and high and accurate population-
based coverage of all tumours, such as those in the UK.9,12,13JHEP Reports 2021Patients who do not initially have their cancer registered
should be picked up through death certificate only (DCO) regis-
trations. This method permitted more specific analyses by PLC
subtype by taking into account the rich diagnostic data including
morphology. The main advantage of this method is that it avoids
including deaths from other cancers, in particular extrahepatic
CCA, that were coded as PLCs on the death certificate.
Some between-nation comparisons were not possible owing
to small numbers and lack of statistical power. This was a
particular problem for smaller subgroups including the ‘Other’
liver cancer category, and diagnoses and deaths in NI. In addition,
cause of death in the data was missing for 5.5% of deaths in NI
(compared with approximately 1% in other registries) therefore
mortality will be underestimated. A total of 3,730 incidence
cases, mainly DCO registrations, were excluded from survival
analyses. These cases may have a different risk factor distribution
to those that are included. Excluded cases were younger than
included cases, and in England slightly more likely to be female.5vol. 3 j 100232
Table 2. Hepatocellular carcinoma age-standardised incidence and incidence-based mortality rates 1997–2017, by nation, sex, subtype, and year.
Incidence
UK England Scotland Wales Northern Ireland
N cases ASR 95% CI N cases ASR 95% CI N cases ASR 95% CI N cases ASR 95% CI N cases ASR 95% CI
Persons
1997 884 1.82 (1.70–1.94) 672 1.66 (1.53–1.79) 145 3.40 (2.87–4.00) 53 2.00 (1.50–2.62) 14 1.19 (0.65–2.00)
2007 1,873 3.54 (3.38–3.71) 1,469 3.33 (3.16–3.50) 243 5.24 (4.6–5.95) 106 3.74 (3.06–4.53) 55 4.21 (3.17–5.49)
2017 3,368 5.45 (5.27–5.64) 2,711 5.25 (5.05–5.45) 409 7.71 (6.98–8.50) 169 5.23 (4.47–6.08) 79 4.95 (3.92–6.17)
Men
1997 647 3.03 (2.80–3.28) 487 2.73 (2.49–2.99) 111 5.99 (4.91–7.24) 40 3.55 (2.53–4.84) 9 1.75 (0.79–3.35)
2007 1,449 6.04 (5.73–6.37) 1,128 5.63 (5.31–5.98) 199 9.71 (8.38–11.19) 80 6.12 (4.84–7.62) 42 7.13 (5.10–9.68)
2017 2,643 9.22 (8.87–9.58) 2,127 8.87 (8.49–9.26) 321 13.31 (11.87–14.87) 131 8.62 (7.20–10.24) 64 8.66 (6.65–11.08)
Women
1997 237 0.87 (0.77–0.99) 185 0.82 (0.70–0.95) 34 1.43 (0.99–2.00) 13 0.87 (0.46–1.50) 5 0.72 (0.23–1.67)
2007 424 1.45 (1.31–1.59) 341 1.39 (1.25–1.55) 44 1.73 (1.25–2.32) 26 1.66 (1.08–2.45) 13 1.78 (0.94–3.05)
2017 725 2.17 (2.02–2.34) 584 2.09 (1.92–2.27) 88 3.08 (2.47–3.80) 38 2.19 (1.54–3.01) 15 1.80 (1.01–2.98)
Incidence-based mortality
UK England Scotland Wales Northern Ireland
N cases ASMR 95% CI N cases ASMR 95% CI N cases ASMR 95% CI N cases ASMR 95% CI N cases ASMR 95% CI
Persons
1999 657 1.33 (1.23–1.44) 520 1.26 (1.16–1.38) 82 1.95 (1.55–2.42) 43 1.63 (1.18–2.20) 12 1.01 (0.52–1.77)
2007 1,278 2.44 (2.30–2.57) 987 2.26 (2.12–2.40) 184 3.96 (3.41–4.58) 72 2.56 (2–3.22) 35 2.74 (1.90–3.82)
2017 2,456 3.98 (3.82–4.14) 1,953 3.79 (3.62–3.96) 323 6.12 (5.47–6.83) 131 4.01 (3.35–4.75) 49 3.08 (2.27–4.07)
Men
1999 463 2.11 (1.92–2.32) 372 2.01 (1.81–2.23) 56 3.16 (2.34–4.17) 26 2.24 (1.45–3.29) 9 1.75 (0.77–3.37)
2007 992 4.19 (3.93–4.46) 764 3.87 (3.59–4.15) 149 7.29 (6.14–8.58) 52 4.01 (2.99–5.27) 27 4.72 (3.09–6.90)
2017 1,918 6.74 (6.44–7.05) 1,528 6.41 (6.09–6.74) 244 10.33 (9.05–11.73) 106 6.96 (5.69–8.43) 40 5.55 (3.95–7.57)
Women
1999 194 0.69 (0.60–0.80) 148 0.64 (0.54–0.75) 26 1.04 (0.68–1.52) 17 1.12 (0.65–1.8) 3 0.44 (0.09–1.28)
2007 286 0.99 (0.88–1.11) 223 0.92 (0.80–1.05) 35 1.37 (0.95–1.91) 20 1.31 (0.80–2.03) 8 1.14 (0.49–2.25)
2017 538 1.61 (1.48–1.76) 425 1.53 (1.38–1.68) 79 2.74 (2.17–3.42) 25 1.41 (0.91–2.09) 9 1.05 (0.48–2.00)









Table 3. Primary liver cancer age-standardised net-survival by nation, sex, subtype, and 5-year cohort.
Cohort
UK England Scotland Wa Northern Ireland
N Net survival 95% CI N Net survival 95% CI N Net survival 95% CI N Net surviv 95% CI N Net survival 95% CI
1-year survival
PLC
1997–2001 11,036 21.7 (20.9–22.5) 9,001 21.4 (20.5–22.3) 1,177 25.4 (22.8–28.0) 632 20 (17.5–24) 226 18.6 (13.8–24.1)
2013–2017* 29,029 40.6 (40.0–41.2) 23,773 40.2 (39.6–40.9) 3,107 44.6 (42.8–46.4) 1,487 3 (35.2–40.3) 656 39.9 (36.0–43.7)
Total change 18.9 18.8 19.2 1 21.3
HCC
1997–2001 4,757 23.7 (22.5–24.9) 3,865 23.6 (22.3–25.0) 564 27.3 (23.6–31.1) 239 1 (13.2–23) 89 21.1 (13.2–30.3)
2013–2017* 16,091 46.7 (45.9–47.5) 12,781 46.2 (45.3–47.1) 2,052 52.4 (50.1–54.6) 808 42 (38.5–45.5) 432 45.4 (40.5–50.1)
Total change 23.0 22.6 25.1 24 24.3
ICCA
1997–2001 4,573 22.6 (21.4–23.9) 3,711 22.2 (20.9–23.6) 488 25.3 (21.4–29.4) 264 26 (21.3–32.2) 110 14.6 (8.7–22.1)
2013–2017* 9,795 30.5 (29.6–31.4) 8,109 30.7 (29.7–31.7) 958 28.5 (25.6–31.5) 568 30 (27.1–34.9) 173 28.3 (21.6–35.3)
Total change 7.9 8.5 3.2 4 13.7
Other
1997–2001 1,648 13.2 (11.6–14.9) 1,397 12.9 (11.2–14.8) 108 15.5 (9.3–23.2) 117 15 (9.8–23.2) 26 13.2 (3.6–29.2)
2013–2017* 3,065 37.9 (36.1–39.6) 2,831 38.2 (36.3–40.0) Insuff 102 4 (31.4–51.1) 50 27.5 (15.8–40.7)
Total change 24.7 25.3 NC 25 14.3
2-year survival
PLC
1997–2001 2,300 12.8 (12.1–13.4) 1,848 12.7 (12–13.4) 286 13.6 (11.6–15.8) 126 13 (11.1–16.6) 41 7.0 (4.1–11.1)
2012–2016* 10,753 27.2 (26.6–27.7) 8,686 26.7 (26.1–27.3) 1,286 31.4 (29.7–33.2) 530 25 (23.0–27.7) 241 26.1 (22.6–29.7)
Total change 14.4 14.0 17.8 1 19.1
HCC
1997–2001 1,085 15.4 (14.3–16.5) 879 15.5 (14.3–16.7) 148 15.6 (12.6–18.9) 41 12 (8.3–16.9) 18 11.6 (5.7–19.8)
2012–2016* 6,783 33.8 (33.0–34.6) 5,277 33.1 (32.2–34.0) 1,002 39.7 (37.4–42.0) 326 3 (28.7–35.5) 185 31.4 (26.8–36)
Total change 18.4 17.6 24.1 19 19.8
ICCA
1997–2001 993 11.0 (10.1–12.0) 791 10.7 (9.7–11.8) 118 11.9 (9.1–15.1) 67 18 (14.0–23.8) 15 2.4 (0.6–7.0)
2012–2016* 2,739 15.8 (15.0–16.6) 2,273 16.1 (15.3–17) 255 13.4 (11.2–15.8) 157 1 (11.3–17.3) 42 14.6 (9.4–20.8)
Total change 4.8 5.4 1.5 -4 12.2
Other
1997–2001 208 8.5 (7.1–9.9) 172 8.7 (7.2–10.3) 16 7.0 (3.1–13.1) 2 year>1 year <10
2012–2016* 1,139 24.4 (22.9–26) 1,066 24.5 (22.9–26.2) 14 12.7 (6.1–21.9) 40 32 (23.1–42.5) 18 10.0 (3.3–21.4)
Total change 15.9 15.8 5.7 NC NC
5-year survival
PLC
1997–2001 1,300 7.2 (6.7–7.8) 1,053 7 (6.4–7.6) 146 8.5 (6.8–10.5) 81 (6.8–11.8) 14 3.8 (1.6–7.5)
2009–2013* 5,018 14.3 (13.8–14.8) 3,975 13.9 (13.3–14.4) 647 18.4 (16.6–20.2) 253 14 (11.9–16.3) 123 14.2 (11.0–17.9)
Total change 7.1 6.9 9.9 4 10.4











































































































































































































































































































































































































































































































































































































































































JHEP Reports 2021The liver is a common site of metastases and registry staff are
trained to identify primary from secondary disease using mul-
tiple data sources, however, in some cases this may not have
been possible and therefore some cancers included (particularly
in the ‘Other’ category), may actually have been metastases
incorrectly recorded as liver primaries. This would result in an
overestimation of incidence and mortality; however, this would
be less than standard mortality estimations that rely on death
certificate information only. It is also possible some in the ‘Other’
category are actually HCCs or ICCAs with insufficient information
provided to categorise them correctly at registration. Diagnosis is
more likely to be based on the death certificate only in this
category. Additionally, when English data records were linked to
hospital episodes statistics data, 25% of other liver tumours were
identified as having cirrhosis (compared with 57% of HCCs and
11% % of ICCAs, method detailed in Driver et al.14). This indicates
there are likely to be some HCCs in this category, but this will not
account for all unspecified liver tumours.
In the ICD-10 coding system, there is currently no specific
code for perihilar CCA (frequently cited as the most common
subtype of CCA, followed by distal, and then intrahepatic15,16).
There is a specific morphology code in ICD-O-2 (8162), which can
be mapped to either C22.1 or C24, but it is rarely used. All 298
ICCA tumours with this code were excluded, however, as 75% of
all CCAs in the English registry are coded as intrahepatic it is
likely many perihilar CCAs remain included. This makes com-
parison of ICCA rates in other countries that systematically code
perihilar as extrahepatic challenging.17 The NI cancer registry is
more likely to code CCA as extrahepatic than the English cancer
registry (65% of all CCAs in NI vs. 25% in England) therefore the
lower rates of ICCA, and hence overall PLC, apparent in NI are
likely as a result of differences in coding. The WHO Classification
of tumours recommended the addition of C24.3 to ICD-O-2 for
perihilar CCA, and this has been adopted by the English, Welsh,
and NI cancer registries for data from 2018.
Interpretation and comparison with other studies
The high increase in rates of liver cancer found here are in line
with estimates from global studies, which found the annual
percentage change in the UK to be amongst the highest in the
world.2,18–20 This increase in PLC incidence and mortality, in
particular for HCC, mirror the substantial increase in cirrhosis21
and liver disease mortality22 over this time. The risk factors for
liver disease and HCC are well-established, and geographical and
temporal variation in their distribution largely explain differ-
ences in PLC rates between countries and over time.2 An
extensive analysis of the leading causes of PLC worldwide found
in the UK in 2016 these were, in descending order, hepatitis C
(HCV), alcohol consumption, ‘other causes’, and hepatitis B.2 This
penultimate category, which includes metabolic factors such as
obesity, diabetes, and non-alcoholic fatty liver disease (NAFLD)
alongside other factors such as aflatoxin B1 and tobacco, was the
fastest growing category. Although the relative risk of HCC from
obesity and alcohol are lower than for viral hepatitis, these fac-
tors are more prevalent in the population and therefore are
responsible for a substantial proportion of cases.23 The propor-
tion of individuals with obesity or diabetes has increased sub-
stantially over this period.24 The timing of the plateau in HCC
incidence has coincided with the era of direct acting antivirals
(DAAs – highly potent and well-tolerated drugs for the treatment
of HCV).25 The rate of transplants as a result of cirrhosis or HCC
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Fig. 2. Age-standardised net-survival in all persons by nation and subtype. (A) Primary liver cancer; (B) hepatocellular carcinoma; (C) intrahepatic chol-
angiocarcinoma; (D) other and unspecified liver tumours. Estimates from 5-year rolling cohorts.the rate of HCV-related mortality in England.27 Data from the US
have shown sustained virologic response induced by DAAs to be
associated with an approximately 70% reduced risk of de novo
HCC in HCV-infected patients.28,29 An Australian study also re-
ported a plateau in the incidence of HCC in patients with HCV in
the DAA-era.30 However, in the US incidence rates of HCC have
plateaued since 2013, and DAAs were not available until late
2014, suggesting other factors may be involved.31 Heavy drink-
ing32 and HCV infection33 are more prevalent in Scotland,
particularly in men, and may explain the higher HCC incidence
rates seen. The concurrent increase in HCC and ICCA incidence
points to some shared risk factors. Cirrhosis substantially in-
creases risk of ICCA (odds ratio 15.3),34 therefore the increase in
liver disease in the UK may explain some of the rise in ICCA.
EUROCARE-5 explored relative survival following a PLC
diagnosis in Europe between 1999 and 2007.4 As with our figures
for this period, 1-year survival was found to be between 20% and
30% and 5-year survival to be below 10%, which was around the
European average. Although some improvements in survival
were seen over the EUROCARE-5 study duration, our findings
indicate substantially greater improvement in the past 10 years.
The improvement in short-, medium-, and longer-term HCCJHEP Reports 2021survival suggests a migration to earlier stage at presentation and/
or improvements in treatments, both curative and palliative.
There have been many advances in treatment options over the
past 20 years, including in systemic chemotherapy such as sor-
afenib, multiple embolization, and ablation techniques, and
innovation and increase in the number of liver transplantations,
which offers a cure to both the cancer and the underlying liver
disease.35 During this time clinical decision-making in cancer
care has increasingly shifted to multidisciplinary teams,36 which
has been attributed as a factor improving survival for other
cancers.37,38 The proportion of cancers diagnosed via surveillance
may have increased over this period. Earlier stage at diagnosis as
a result of surveillance could both artefactually increase survival
through lead-time bias and genuinely increase it through iden-
tification of tumours when both the stage of the cancer and the
liver disease are favourable to curative treatment.39 Despite
improvements, 1-year net survival in the UK remains below 50%.
ICCA survival has not improved dramatically and remains poor at
30%; the majority of ICCA cases occur in patients with no known
risk factors, early disease is asymptomatic and specific and
sensitive markers of early disease do not yet exist,40 making
surveillance and early diagnosis challenging. There are fewer9vol. 3 j 100232
Research articlecurative treatment options as liver transplant is not yet recom-
mended for ICCA although trials are ongoing. Additionally, sur-
vival following treatments such as resection or chemotherapy is
lower than for HCC.
Conclusions
Liver cancer risk factors are largely modifiable and therefore
prevention is possible through lifestyle modifications, vaccina-
tion programs, and widespread, effective treatment for HCV. The
effect of the latter already appears to be visible. However, asJHEP Reports 2021other risk factors such as obesity and diabetes continue to rise
and alcohol misuse remains prevalent in the UK, it is unlikely the
considerable burden of liver disease and consequently liver
cancer will abate. Although substantial improvements in survival
have been made, most likely as a result of the multiple in-
novations in treatments in this field, over half of patients are not
alive after 1 year. Reducing incidence through prevention, and
further progress in identifying those most at risk, and finding
tumours earlier, at a treatable stage, is needed.Abbreviations
AAPC, average annual percentage change; APC, annual percentage
change; ASMR, age-standardised mortality rate; ASR, age-standardised
incidence rate; BASL, British Association for the Study of the Liver; DAA,
direct-acting antivirals; DCO, death certificate only; HCC, hepatocellular
carcinoma HCV, hepatitis C virus; ICCA, intrahepatic cholangiocarcinoma;
ICD-10, International Classification of Diseases 10th Edition; ICD-O, In-
ternational Classification of Diseases for Oncology; NAFLD, non-alcoholic
fatty liver disease; NCRAS, National Cancer Registration and Analysis
Service; NI, Northern Ireland; PLC, primary liver cancer.
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